Table of Contents

2019-2024 Global Osteoarthritis Pain Drugs Consumption Market Report

1 Scope of the Report

• 1.1 Market Introduction
• 1.2 Research Objectives
• 1.3 Years Considered
• 1.4 Market Research Methodology
• 1.5 Economic Indicators
• 1.6 Currency Considered

2 Executive Summary

• 2.1 World Market Overview
  • 2.1.1 Global Osteoarthritis Pain Drugs Consumption 2014-2024
  • 2.1.2 Osteoarthritis Pain Drugs Consumption CAGR by Region
• 2.2 Osteoarthritis Pain Drugs Segment by Type
  • 2.2.1 Oral
  • 2.2.2 Injection
  • 2.2.3 External
• 2.3 Osteoarthritis Pain Drugs Consumption by Type
  • 2.3.1 Global Osteoarthritis Pain Drugs Consumption Market Share by Type (2014-2019)
  • 2.3.2 Global Osteoarthritis Pain Drugs Revenue and Market Share by Type (2014-2019)
  • 2.3.3 Global Osteoarthritis Pain Drugs Sale Price by Type (2014-2019)
• 2.4 Osteoarthritis Pain Drugs Segment by Application
  • 2.4.1 Medical Care
  • 2.4.2 Personal Care
• 2.5 Osteoarthritis Pain Drugs Consumption by Application
  • 2.5.1 Global Osteoarthritis Pain Drugs Consumption Market Share by Application (2014-2019)
  • 2.5.2 Global Osteoarthritis Pain Drugs Value and Market Share by Application (2014-2019)
  • 2.5.3 Global Osteoarthritis Pain Drugs Sale Price by Application (2014-2019)

3 Global Osteoarthritis Pain Drugs by Players

• 3.1 Global Osteoarthritis Pain Drugs Sales Market Share by Players
  • 3.1.1 Global Osteoarthritis Pain Drugs Sales by Players (2017-2019)
  • 3.1.2 Global Osteoarthritis Pain Drugs Sales Market Share by Players (2017-2019)
• 3.2 Global Osteoarthritis Pain Drugs Revenue Market Share by Players
  • 3.2.1 Global Osteoarthritis Pain Drugs Revenue by Players (2017-2019)
  • 3.2.2 Global Osteoarthritis Pain Drugs Revenue Market Share by Players (2017-2019)
• 3.3 Global Osteoarthritis Pain Drugs Sale Price by Players
• 3.4 Global Osteoarthritis Pain Drugs Manufacturing Base Distribution, Sales Area, Product Types by Players
  • 3.4.1 Global Osteoarthritis Pain Drugs Manufacturing Base Distribution and Sales Area by Players
  • 3.4.2 Players Osteoarthritis Pain Drugs Products Offered
• 3.5 Market Concentration Rate Analysis
  • 3.5.1 Competition Landscape Analysis
  • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
• 3.6 New Products and Potential Entrants
• 3.7 Mergers & Acquisitions, Expansion

4 Osteoarthritis Pain Drugs by Regions

• 4.1 Osteoarthritis Pain Drugs by Regions
  • 4.1.1 Global Osteoarthritis Pain Drugs Consumption by Regions
  • 4.1.2 Global Osteoarthritis Pain Drugs Value by Regions
• 4.2 Americas Osteoarthritis Pain Drugs Consumption Growth
• 4.3 APAC Osteoarthritis Pain Drugs Consumption Growth
• 4.4 Europe Osteoarthritis Pain Drugs Consumption Growth
• 4.5 Middle East & Africa Osteoarthritis Pain Drugs Consumption Growth

5 Americas

• 5.1 Americas Osteoarthritis Pain Drugs Consumption by Countries
  • 5.1.1 Americas Osteoarthritis Pain Drugs Consumption by Countries (2014-2019)
  • 5.1.2 Americas Osteoarthritis Pain Drugs Value by Countries (2014-2019)
• 5.2 Americas Osteoarthritis Pain Drugs Consumption by Type
• 5.3 Americas Osteoarthritis Pain Drugs Consumption by Application
• 5.4 United States
• 5.5 Canada
• 5.6 Mexico
• 5.7 Key Economic Indicators of Few Americas Countries

6 APAC

• 6.1 APAC Osteoarthritis Pain Drugs Consumption by Countries
  • 6.1.1 APAC Osteoarthritis Pain Drugs Consumption by Countries (2014-2019)
  • 6.1.2 APAC Osteoarthritis Pain Drugs Value by Countries (2014-2019)
• 6.2 APAC Osteoarthritis Pain Drugs Consumption by Type
• 6.3 APAC Osteoarthritis Pain Drugs Consumption by Application
• 6.4 China
• 6.5 Japan
• 6.6 Korea
• 6.7 Southeast Asia
• 6.8 India
• 6.9 Australia
• 6.10 Key Economic Indicators of Few APAC Countries

7 Europe

• 7.1 Europe Osteoarthritis Pain Drugs by Countries
  • 7.1.1 Europe Osteoarthritis Pain Drugs Consumption by Countries (2014-2019)
  • 7.1.2 Europe Osteoarthritis Pain Drugs Value by Countries (2014-2019)
• 7.2 Europe Osteoarthritis Pain Drugs Consumption by Type
• 7.3 Europe Osteoarthritis Pain Drugs Consumption by Application
• 7.4 Germany
• 7.5 France
• 7.6 UK
• 7.7 Italy
• 7.8 Russia
• 7.9 Spain
• 7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa

• 8.1 Middle East & Africa Osteoarthritis Pain Drugs by Countries
  • 8.1.1 Middle East & Africa Osteoarthritis Pain Drugs Consumption by Countries (2014-2019)
  • 8.1.2 Middle East & Africa Osteoarthritis Pain Drugs Value by Countries (2014-2019)
• 8.2 Middle East & Africa Osteoarthritis Pain Drugs Consumption by Type
• 8.3 Middle East & Africa Osteoarthritis Pain Drugs Consumption by Application
• 8.4 Egypt
• 8.5 South Africa
• 8.6 Israel
• 8.7 Turkey
• 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

• 9.1 Market Drivers and Impact
  • 9.1.1 Growing Demand from Key Regions
  • 9.1.2 Growing Demand from Key Applications and Potential Industries
• 9.2 Market Challenges and Impact
• 9.3 Market Trends

10 Marketing, Distributors and Customer

• 10.1 Sales Channel
  • 10.1.1 Direct Channels
  • 10.1.2 Indirect Channels
• 10.2 Osteoarthritis Pain Drugs Distributors
• 10.3 Osteoarthritis Pain Drugs Customer

11 Global Osteoarthritis Pain Drugs Market Forecast

• 11.1 Global Osteoarthritis Pain Drugs Consumption Forecast (2019-2024)
• 11.2 Global Osteoarthritis Pain Drugs Forecast by Regions
  • 11.2.1 Global Osteoarthritis Pain Drugs Forecast by Regions (2019-2024)
  • 11.2.2 Global Osteoarthritis Pain Drugs Value Forecast by Regions (2019-2024)
  • 11.2.3 Americas Consumption Forecast
  • 11.2.4 APAC Consumption Forecast
  • 11.2.5 Europe Consumption Forecast
  • 11.2.6 Middle East & Africa Consumption Forecast
• 11.3 Americas Forecast by Countries
  • 11.3.1 United States Market Forecast
  • 11.3.2 Canada Market Forecast
  • 11.3.3 Mexico Market Forecast
  • 11.3.4 Brazil Market Forecast
• 11.4 APAC Forecast by Countries
  • 11.4.1 China Market Forecast
  • 11.4.2 Japan Market Forecast
  • 11.4.3 Korea Market Forecast
  • 11.4.4 Southeast Asia Market Forecast
  • 11.4.5 India Market Forecast
  • 11.4.6 Australia Market Forecast
• 11.5 Europe Forecast by Countries
  • 11.5.1 Germany Market Forecast
  • 11.5.2 France Market Forecast
  • 11.5.3 UK Market Forecast
  • 11.5.4 Italy Market Forecast
  • 11.5.5 Russia Market Forecast
  • 11.5.6 Spain Market Forecast
• 11.6 Middle East & Africa Forecast by Countries
  • 11.6.1 Egypt Market Forecast
  • 11.6.2 South Africa Market Forecast
  • 11.6.3 Israel Market Forecast
  • 11.6.4 Turkey Market Forecast
  • 11.6.5 GCC Countries Market Forecast
• 11.7 Global Osteoarthritis Pain Drugs Forecast by Type
• 11.8 Global Osteoarthritis Pain Drugs Forecast by Application

12 Key Players Analysis

• 12.1 Johnson & Johnson
  • 12.1.1 Company Details
  • 12.1.2 Osteoarthritis Pain Drugs Product Offered
  • 12.1.3 Johnson & Johnson Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.1.4 Main Business Overview
  • 12.1.5 Johnson & Johnson News
• 12.2 Pfizer
  • 12.2.1 Company Details
  • 12.2.2 Osteoarthritis Pain Drugs Product Offered
  • 12.2.3 Pfizer Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.2.4 Main Business Overview
  • 12.2.5 Pfizer News
• 12.3 GlaxoSmithKline
  • 12.3.1 Company Details
  • 12.3.2 Osteoarthritis Pain Drugs Product Offered
  • 12.3.3 GlaxoSmithKline Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.3.4 Main Business Overview
  • 12.3.5 GlaxoSmithKline News
• 12.4 Mylan
  • 12.4.1 Company Details
  • 12.4.2 Osteoarthritis Pain Drugs Product Offered
  • 12.4.3 Mylan Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.4.4 Main Business Overview
  • 12.4.5 Mylan News
• 12.5 Lilly
  • 12.5.1 Company Details
  • 12.5.2 Osteoarthritis Pain Drugs Product Offered
  • 12.5.3 Lilly Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.5.4 Main Business Overview
  • 12.5.5 Lilly News
• 12.6 Sanofi
  • 12.6.1 Company Details
  • 12.6.2 Osteoarthritis Pain Drugs Product Offered
  • 12.6.3 Sanofi Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.6.4 Main Business Overview
  • 12.6.5 Sanofi News
• 12.7 Abbott Laboratories
  • 12.7.1 Company Details
  • 12.7.2 Osteoarthritis Pain Drugs Product Offered
  • 12.7.3 Abbott Laboratories Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.7.4 Main Business Overview
  • 12.7.5 Abbott Laboratories News
• 12.8 Bayer
  • 12.8.1 Company Details
  • 12.8.2 Osteoarthritis Pain Drugs Product Offered
  • 12.8.3 Bayer Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.8.4 Main Business Overview
  • 12.8.5 Bayer News
• 12.9 Almatica Pharma
  • 12.9.1 Company Details
  • 12.9.2 Osteoarthritis Pain Drugs Product Offered
  • 12.9.3 Almatica Pharma Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.9.4 Main Business Overview
  • 12.9.5 Almatica Pharma News
• 12.10 TEVA
  • 12.10.1 Company Details
  • 12.10.2 Osteoarthritis Pain Drugs Product Offered
  • 12.10.3 TEVA Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.10.4 Main Business Overview
  • 12.10.5 TEVA News
• 12.11 Iroko Pharmaceuticals

13 Research Findings and Conclusion

The main role of osteoarthritis pain drugs is to relieve pain, and cannot slow the progress of osteoarthritis, osteoarthritis in the use of two kinds of painkillers:

Painkillers only: Only a simple analgesic effect, but no anti-inflammatory function, such as acetaminophen, tramadol. Acetaminophen side effects, but the analgesic effect is relatively weak, mainly for mild to moderate pain; tramadol analgesic effect is strong, but also side effects are larger, mainly gastrointestinal side effects such as nausea, vomiting and so on.

NSAIDs: With both anti-inflammatory and analgesic effect, suitable for inflammatory pain, for the acute phase of osteoarthritis, joint swelling of the patients to relieve symptoms better. These drugs may lead to nausea, vomiting and other gastrointestinal discomfort, but also increase the risk of gastrointestinal bleeding, so patients with gastro duodenal ulcer in the application of these drugs should consult a digestive physician, plus gastric mucosal protection Drugs or antacid drugs.

Medicines for Osteoarthritis Pain are available as pills, syrups, creams or lotions, or they are injected into a joint.

Osteoarthritis, the most common type of arthritis, is a leading cause of disability. It is a chronic, progressive degenerative joint disease, which is characterized by gradual destruction of the articular cartilage, hypertrophy of the bone margins, and a series of biochemical and morphological changes in the synovial membrane and joint capsule. This results in pain and loss of movement.
The USA osteoarthritis pain drugs market is very concerted market; the revenue of eleven manufacturers accounts about 88% of the total revenue in 2016. The high-end products mainly come from USA and Europe.
The leading manufactures mainly are Johnson & Johnson, Pfizer and GlaxoSmithKline. Johnson & Johnson is the largest manufacturer; its revenue of USA market exceeds 27% in 2016. The next is Pfizer and GlaxoSmithKline.

According to this study, over the next five years the Osteoarthritis Pain Drugs market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Osteoarthritis Pain Drugs business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Osteoarthritis Pain Drugs market by product type, application, key manufacturers and key regions and countries.

This study considers the Osteoarthritis Pain Drugs value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Oral
Injection
External
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Medical Care
Personal Care

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Johnson & Johnson
Pfizer
GlaxoSmithKline
Mylan
Lilly
Sanofi
Abbott Laboratories
Bayer
Almatica Pharma
TEVA
Iroko Pharmaceuticals

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Osteoarthritis Pain Drugs consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Osteoarthritis Pain Drugs market by identifying its various subsegments.
Focuses on the key global Osteoarthritis Pain Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Osteoarthritis Pain Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Osteoarthritis Pain Drugs submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.